{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:22:47Z","timestamp":1791976967636,"version":"4.4.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Council","award":["MR\/L005123\/1"],"award-info":[{"award-number":["MR\/L005123\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction:<\/jats:title><jats:p>Targeted biologic therapies demonstrate similar efficacies in rheumatoid arthritis despite distinct mechanisms of action. They also exhibit a ceiling effect, with 10% to 20% of patients achieving remission in clinical trials. None of these therapies target synovial fibroblasts, which drive and maintain synovitis. Seliciclib (R-roscovitine) is an orally available cyclin-dependent kinase inhibitor that suppresses fibroblast proliferation, and is efficacious in preclinical arthritis models. We aim to determine the toxicity and preliminary efficacy of seliciclib in combination with biologic therapies, to inform its potential as an adjunctive therapy in rheumatoid arthritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis:<\/jats:title><jats:p>TRAFIC is a non-commercial, multi-center, rolling phase Ib\/IIa trial investigating the safety, tolerability, and efficacy of seliciclib in patients with moderate to severe rheumatoid arthritis receiving biologic therapies. All participants receive seliciclib with no control arm. The primary objective of part 1 (phase Ib) is to determine the maximum tolerated dose and safety of seliciclib over 4 weeks of dosing. Part 1 uses a restricted 1-stage Bayesian continual reassessment method based on a target dose-limiting toxicity probability of 35%. Part 2 (phase IIa) assesses the potential efficacy of seliciclib, and is designed as a single arm, single stage early phase trial based on a Fleming-A\u2019Hern design using the maximum tolerated dose recommended from part 1. The primary response outcome after 12 weeks of therapy is a composite of clinical, histological and magnetic resonance imaging scores. Secondary outcomes include adverse events, pharmacodynamic and pharmacokinetic parameters, autoantibodies, and fatigue.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination:<\/jats:title><jats:p>The study has been reviewed and approved by the North East - Tyne &amp; Wear South Research Ethics Committee (reference 14\/NE\/1075) and the Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom. Results will be disseminated through publication in relevant peer-reviewed journals and presentation at national and international conferences.<\/jats:p><jats:p><jats:bold>Trials Registration:<\/jats:bold>ISRCTN, ISRCTN36667085. Registered on September 26, 2014; http:\/\/www.isrctn.com\/ISRCTN36667085<\/jats:p><jats:p><jats:bold>Current protocol version<\/jats:bold>: Protocol version 11.0 (March 21, 2019)<\/jats:p><\/jats:sec>","DOI":"10.1097\/md.0000000000020458","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T18:43:33Z","timestamp":1592937813000},"page":"e20458","source":"Crossref","is-referenced-by-count":23,"title":["Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7311","authenticated-orcid":false,"given":"Stefan","family":"Siebert","sequence":"first","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur G.","family":"Pratt","sequence":"additional","affiliation":[{"name":"Translational and Experimental Medicine Institute, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah D.","family":"Stocken","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Morton","sequence":"additional","affiliation":[{"name":"Institute of Health and Society, Newcastle University, Newcastle upon Tyne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Cranston","sequence":"additional","affiliation":[{"name":"Institute of Health and Society, Newcastle University, Newcastle upon Tyne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cole","sequence":"additional","affiliation":[{"name":"Institute of Health and Society, Newcastle University, Newcastle upon Tyne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheelagh","family":"Frame","sequence":"additional","affiliation":[{"name":"Cyclacel Ltd., Dundee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Buckley","sequence":"additional","affiliation":[{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and Institute for Inflammation and Ageing, University of Birmingham, Birmingham"},{"name":"Kennedy Institute of Rheumatology, Roosevelt Drive, Headington University of Oxford, Oxford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Fai","family":"Ng","sequence":"additional","affiliation":[{"name":"Translational and Experimental Medicine Institute, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Filer","sequence":"additional","affiliation":[{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and Institute for Inflammation and Ageing, University of Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Translational and Experimental Medicine Institute, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet (London, England)"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/art.1780300504","article-title":"The work dynamics of the person with rheumatoid arthritis","volume":"30","author":"Yelin","year":"1987","journal-title":"Arthritis Rheum"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1517\/14712590903379494","article-title":"Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists","volume":"9","author":"Isaacs","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/keq045","article-title":"Neutrophil function in inflammation and inflammatory diseases","volume":"49","author":"Wright","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol Rev"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11926-012-0272-4","article-title":"Managing macrophages in rheumatoid arthritis by reform or removal","volume":"14","author":"Li","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4161\/cbt.19589","article-title":"Cyclin dependent kinases in cancer: potential for therapeutic intervention","volume":"13","author":"Canavese","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4049\/jimmunol.170.2.838","article-title":"IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts","volume":"170","author":"Perlman","year":"2003","journal-title":"J Immunol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.4049\/jimmunol.171.9.4913","article-title":"Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis","volume":"171","author":"Nonomura","year":"2003","journal-title":"J Immunol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.4049\/jimmunol.165.12.7246","article-title":"Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice","volume":"165","author":"Nasu","year":"2000","journal-title":"J Immunol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.10738","article-title":"In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)","volume":"102","author":"McClue","year":"2002","journal-title":"Int J Cancer"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1517\/13543784.12.6.955","article-title":"CDK inhibitors in clinical development for the treatment of cancer","volume":"12","author":"Fischer","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/excr.1998.4216","article-title":"The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity","volume":"245","author":"Alessi","year":"1998","journal-title":"Exp Cell Res"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/art.33311","article-title":"Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis","volume":"64","author":"Mavers","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/art.22132","article-title":"Regulation of Mcl-1 expression in rheumatoid arthritis synovial macrophages","volume":"54","author":"Liu","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R17-20230915","first-page":"785","article-title":"The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382","volume":"60","author":"Ljungman","year":"2001","journal-title":"Mol Pharmacol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1038\/sj.onc.1204412","article-title":"Activation of p53 by roscovitine-mediated suppression of MDM2 expression","volume":"20","author":"Lu","year":"2001","journal-title":"Oncogene"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1083\/jcb.200201024","article-title":"Cyclin-dependent kinases govern formation and maintenance of the nucleolus","volume":"156","author":"Sirri","year":"2002","journal-title":"J Cell Biol"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1158\/0008-5472.CAN-03-0110","article-title":"The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway","volume":"64","author":"Whittaker","year":"2004","journal-title":"Cancer Res"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nm1468","article-title":"Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis","volume":"12","author":"Rossi","year":"2006","journal-title":"Nat Med"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.4049\/jimmunol.180.3.1954","article-title":"Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors","volume":"180","author":"Sekine","year":"2008","journal-title":"J Immunol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"e30128","DOI":"10.1371\/journal.pone.0030128","article-title":"Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/jcmm.13414","article-title":"CDK7 inhibition suppresses rheumatoid arthritis inflammation via blockage of NF \u03baB activation and IL-1\u03b2\/IL-6 secretion","volume":"22","author":"Hong","year":"2018","journal-title":"J Cell Mol Med"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"31441","DOI":"10.1038\/srep31441","article-title":"Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis","volume":"6","author":"Hellvard","year":"2016","journal-title":"Sci Rep"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","article-title":"Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies","volume":"46","author":"Le Tourneau","year":"2010","journal-title":"Eur J Cancer"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/annrheumdis-2014-205566","article-title":"Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression","volume":"75","author":"Hosoya","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","article-title":"The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions","volume":"44","author":"Kinder","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A\u2019Hern","year":"2001","journal-title":"Stat Med"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1002\/art.20664","article-title":"Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis","volume":"50","author":"Gerlag","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2004.029751","article-title":"Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis","volume":"64","author":"Haringman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/ard.62.8.715","article-title":"Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis","volume":"62","author":"Haringman","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1002\/art.22964","article-title":"Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker","volume":"56","author":"Wijbrandts","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R38-20230915","first-page":"1385","article-title":"OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system","volume":"30","author":"\u00d8stergaard","year":"2003","journal-title":"J Rheumatol"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3899\/jrheum.161433","article-title":"The OMERACT rheumatoid arthritis magnetic resonance imaging (MRI) scoring system: updated recommendations by the OMERACT MRI in arthritis working group","volume":"44","author":"\u00d8stergaard","year":"2017","journal-title":"J Rheumatol"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00330-017-4736-9","article-title":"Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting","volume":"27","author":"Waterton","year":"2017","journal-title":"Eur Radiol"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2007","journal-title":"Br J Cancer"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/sj.bjc.6602969","article-title":"Experimental designs for phase I and phase I\/II dose-finding studies","volume":"94","author":"O\u2019Quigley","year":"2006","journal-title":"Br J Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T21:07:43Z","timestamp":1696280863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020458"}},"subtitle":["An early phase trial"],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":43,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020458","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]}}}